Novo Nordisk increased operating profit by 18% in 2011

2 February 2012 

Sales growth of 9% is driven by Victoza®, NovoRapid® and Levemir®
Lars Rebien Sørensen, president and CEO: “2011 has been a very positive year for Novo Nordisk, with Victoza®, NovoRapid® and Levemir® continuing to drive strong sales growth. In addition, we saw significant progress for our portfolio of clinical development projects which is very encouraging for the long-term outlook for Novo Nordisk.”
Read more

See CEO Lars Rebien Sørensen on World Business Today:

The history of insulin

Novo Nordisk’s Chief Science Officer Mads Krogsgaard Thomsen explains about diabetes and the discovery of insulin, the development of insulin and the differences of human insulin, modern insulin and the next generation insulin. Hear also about how people with diabetes have to control their blood sugar levels and how insulin research and development has reduced the number of times people with diabetes have to inject themselves.

Click to see the presentation (17 mins)

Challenge: an insulin tablet

Peter Kurtzhals, senior vice president of diabetes research at Novo Nordisk explains about the different types of diabetes and medicine. Hear about how people with diabetes have to try to control their blood sugar levels. It is difficult to get started on injecting themselves with insulin, as they currently have to. Therefore, an insulin tablet would be a big help. Peter Kurtzhals explains what is being done to develop such a tablet and what the challenges are.  

Click on the image to see the presentation (16 mins)